Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Provided By GlobeNewswire
Last update: Aug 7, 2025
CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the second quarter ended June 30, 2025.
Read more at globenewswire.com
